Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial

Results from a Phase I clinical trial show promise in enhancing CAR T-cell therapy for relapsed or treatment-resistant B-cell blood cancers. The study, led by The Ohio State University Comprehensive Cancer Center, could improve therapy options for patients.